Twist Bioscience (NASDAQ:TWST – Get Free Report) had its price objective dropped by Barclays from $215.00 to $130.00 in a report released on Monday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Barclays‘s price target suggests a potential upside of 24.33% from the stock’s previous close.
A number of other brokerages have also recently weighed in on TWST. Jefferies Financial Group set a $125.00 price target on shares of Twist Bioscience in a research note on Thursday. Canaccord Genuity Group dropped their price objective on shares of Twist Bioscience from $205.00 to $150.00 and set a “buy” rating on the stock in a research note on Friday. BWS Financial restated a “sell” rating and issued a $45.00 price objective on shares of Twist Bioscience in a research note on Friday, September 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a report on Monday, September 21st. Finally, UBS Group assumed coverage on shares of Twist Bioscience in a research note on Wednesday, September 9th. They set a “neutral” rating and a $144.00 target price for the company. Seven investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $133.92.
View Our Latest Analysis on TWST
Twist Bioscience Stock Performance
Shares of TWST stock traded down $7.04 during trading hours on Monday, hitting $104.56. The stock had a trading volume of 593,086 shares, compared to its average volume of 1,783,855. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38. The firm has a market capitalization of $6.56 billion, a PE ratio of -49.88 and a beta of 2.25. The stock’s 50 day moving average is $150.23 and its 200 day moving average is $93.07. Twist Bioscience has a twelve month low of $24.41 and a twelve month high of $219.71.
Twist Bioscience (NASDAQ:TWST – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.07. The business had revenue of $126.64 million for the quarter, compared to analysts’ expectations of $123.55 million. Twist Bioscience had a negative net margin of 28.34% and a negative return on equity of 27.53%. The firm’s revenue was up 26.7% compared to the same quarter last year. As a group, research analysts forecast that Twist Bioscience will post -1.52 earnings per share for the current fiscal year.
Insider Activity
In other Twist Bioscience news, CEO Emily Leproust sold 4,573 shares of the business’s stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $135.40, for a total value of $619,184.20. Following the transaction, the chief executive officer directly owned 558,187 shares of the company’s stock, valued at approximately $75,578,519.80. The trade was a 0.81% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Robert F. Werner sold 1,482 shares of the company’s stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $188.88, for a total transaction of $279,920.16. Following the transaction, the chief accounting officer owned 42,917 shares of the company’s stock, valued at approximately $8,106,162.96. The trade was a 3.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 495,279 shares of company stock valued at $80,489,387. 3.08% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in TWST. BlackRock Inc. acquired a new stake in Twist Bioscience in the second quarter valued at $600,191,000. William Blair Investment Management LLC purchased a new stake in shares of Twist Bioscience during the 2nd quarter worth $223,722,000. Bank of America Corp DE purchased a new stake in shares of Twist Bioscience during the 2nd quarter worth $94,922,000. Allspring Global Investments Holdings LLC acquired a new position in shares of Twist Bioscience during the 1st quarter worth $22,563,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Twist Bioscience during the 2nd quarter worth $19,722,000.
Twist Bioscience Company Profile
Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications. The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.
See Also
- Five stocks we like better than Twist Bioscience
- Embraer’s Record Backlog Looks Promising, But Can It Keep Its Margins Climbing?
- Could Big Buybacks Be the Next Catalyst for These 3 AI Stocks?
- 3 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?
- Sandisk’s Sell-Off May Be Losing Steam, But the Biggest Risk Still Looms
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
